Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases

Journal of Clinical Investigation

Volumn 117, Issue 3, 2007, Pages 524-529

  Wynn, Thomas A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMINOPHYLLINE; ANGIOTENSIN II; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CYCLOPHOSPHAMIDE; CYTOKINE RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE A INHIBITOR; GELATINASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 1BETA; OSTEOGENIC PROTEIN 1; PENTOXIFYLLINE; PREDNISONE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RITUXIMAB; SMAD7 PROTEIN; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CHRONIC GRAFT REJECTION; FIBROGENESIS; FIBROPROLIFERATIVE DISEASE; FIBROSIS; HUMAN; KIDNEY DISEASE; LIVER CIRRHOSIS; LUNG FIBROSIS; METASTASIS; MORBIDITY; MORTALITY; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; SYSTEMIC SCLEROSIS; TISSUE REGENERATION;

ANGIOTENSIN II; CELL PROLIFERATION; CHRONIC DISEASE; EMBRYONIC STEM CELLS; FIBROBLASTS; FIBROSIS; HUMANS; INFECTION; NEOVASCULARIZATION, PATHOLOGIC; TRANSFORMING GROWTH FACTOR BETA1; WOUND HEALING;

EID: 33847350691     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31487     Document Type: Review

References (49)

1. Tomasek, J.J., Gabbiani, G., Hinz, B., Chaponnier, C., and Brown, R.A. 2002. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3:349-363.
2. Friedman, S.L. 2004. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 1:98-105.
3. Kumar, V., Abbas, A.K., and Fausto, N. 2005. Tissue renewal and repair: regeneration, healing, and fibrosis. In Pathologic basis of disease. V. Kumar, A.K. Abbas, and N. Fausto, editors. Elsevier Saunders. Philadelphia, Pennsylvania, USA. 87-118.
4. Li, M.O., Wan, Y.Y., Sanjabi, S., Robertson, A.K., and Flavell, R.A. 2006. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24:99-146.
5. Wynn, T.A. 2003. IL-13 effector functions. Annu. Rev. Immunol. 21:425-456.
6. Quan, T.E., Cowper, S.E., and Bucala, R. 2006. The role of circulating fibrocytes in fibrosis. Curr. Rheumatol. Rep. 8:145-150.
7. Pardo, A., and Selman, M. 2006. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc. Am. Thorac. Soc. 3:383-388.
8. Wynn, T.A. 2004. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4:583-594.
9. Meneghin, A., and Hogaboam, C.M. 2007. Infectious disease, the innate immune response, and fibrosis. J. Clin. Invest. 117:530-538. doi:10.1172/JCI30595.
10. Akira, S., and Takeda, K. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499-511.
11. Coelho, A.L., Hogaboam, C.M., and Kunkel, S.L. 2005. Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev. 16:553-560.
12. Kalluri, R., and Neilson, E.G. 2003. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112:1776-1784. doi:10.1172/JCI200320530.
13. Bucala, R., Spiegel, L.A., Chesney, J., Hogan, M., and Cerami, A. 1994. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1:71-81.
14. Iredale, J.P. 2007. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 117:539-548. doi:10.1172/JCI30542.
15. Phillips, R.J., et al. 2004. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 114:438-446. doi:10.1172/JCI200420997.
16. Strieter, R.M., Gomperts, B.N., and Keane, M.P. 2007. The role of CXC chemokines in pulmonary fibrosis. J. Clin. Invest. 117:549-556. doi:10.1172/JCI30562.
17. Moore, B.B., et al. 2005. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol. 166:675-684.
18. Varga, J., and Abraham, D. 2007. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 117:557-567. doi:10.1172/JCI31139.
19. Strehlow, D., and Korn, J.H. 1998. Biology of the scleroderma fibroblast. Curr. Opin. Rheumatol. 10:572-578.
20. Abraham, D.J., and Varga, J. 2005. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 26:587-595.
21. Kaviratne, M., et al. 2004. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J. Immunol. 173:4020-4029.
22. Moustakas, A., and Heldin, C.H. 2005. Non-Smad TGF-beta signals. J. Cell Sci. 118:3573-3584.
23. Wang, Y., Fan, P.S., and Kahaleh, B. 2006. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 54:2271-2279.
24. Markiewicz, M., et al. 2004. The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblasts. Clin. Exp. Rheumatol. 22(Suppl. 33):S31-S34.
25. Hasegawa, M., Fujimoto, M., Takehara, K., and Sato, S. 2005. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J. Dermatol. Sci. 39:1-7.
26. Ong, C.J., et al. 1999. A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol. 196:60-68.
27. Berk, B.C., Fujiwara, K., and Lehoux, S. 2007. ECM remodeling in hypertensive heart disease. J. Clin. Invest. 117:568-575. doi:10.1172/JCI31044.
28. Watanabe, T., Barker, T.A., and Berk, B.C. 2005. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 45:163-169.
29. Rosenkranz, S. 2004. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 63:423-432.
30. Rosenkranz, S., et al. 2002. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am. J. Physiol. Heart Circ. Physiol. 283:H1253-H1262.
31. Li, R.K., et al. 1997. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation. 96:874-881.
32. Albanis, E., and Friedman, S.L. 2006. Antifibrotic agents for liver disease. Am. J. Transplant. 6:12-19.
33. Bataller, R., and Brenner, D.A. 2005. Liver fibrosis. J. Clin. Invest. 115:209-218. doi:10.1172/JCI200524282.
34. Llovet, J.M., et al. 2006. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 131:1758-1767.
35. Fallowfield, J.A., Kendall, T.J., and Iredale, J.P. 2006. Reversal of fibrosis: no longer a pipe dream? Clin. Liver Dis. 10:481-497.
36. Vennervald, B.J., and Dunne, D.W. 2004. Morbidity in schistosomiasis: an update. Curr. Opin. Infect. Dis. 17:439-447.
37. Issa, R., et al. 2004. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology. 126:1795-1808.
38. Duffield, J.S., et al. 2005. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115:56-65. doi:10.1172/JCI200522675.
39. Friedlander, M. 2007. Fibrosis and diseases of the eye. J. Clin. Invest. 117:576-586. doi:10.1172/JCI31030.
40. Strieter, R.M., Belperio, J.A., and Keane, M.P. 2002. CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest. 122(Suppl. 6):298S-301S.
41. Distler, O., et al. 2002. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 4:R11.
42. Del Papa, N., et al. 2006. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 54:2605-2615.
43. Wilkinson-Berka, J.L. 2006. Angiotensin and diabetic retinopathy. Int. J. Biochem. Cell Biol. 38:752-765.
44. Rattner, A., and Nathans, J. 2006. Macular degeneration: recent advances and therapeutic opportunities. Nat. Rev. Neurosci. 7:860-872.
45. Lund, R.D., et al. 2006. Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats. Cloning Stem Cells. 8:189-199.
46. Caplan, A.I., and Dennis, J.E. 2006. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98:1076-1084.
47. Chiaramonte, M.G., Donaldson, D.D., Cheever, A.W., and Wynn, T.A. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 104:777-785.
48. Chiaramonte, M.G., et al. 2003. Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J. Exp. Med. 197:687-701.
49. Chiaramonte, M.G., Cheever, A.W., Malley, J.D., Donaldson, D.D., and Wynn, T.A. 2001. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology. 34:273-282.